Evaxion Biotech Receives Grant Funding to Develop New Polio Vaccine

The Gates Foundation has awarded Evaxion A/S (NASDAQ:EVAX) a grant to use its exclusive AI-Immunology™ technology to develop a new polio vaccine.

Evaxion Biotech receives grant funding to develop new polio vaccine

Person in a lab coat looking through a microscope examining cells for research into a new vaccine.

The funds will be used to support research into identifying and combining antigens to create a new vaccine design that does not utilize live viruses. By developing a safer and more effective substitute for conventional polio vaccines, this project seeks to mitigate the persistent risks of polio reappearance without placing a financial strain on Evaxion A/S (NASDAQ:EVAX).

Polio is still a problem in the world today, even after decades of immunization attempts. Existing vaccinations use live or inactivated virus constructions, which can be dangerous in some situations. The clinically validated AI-Immunology™ platform from Evaxion A/S (NASDAQ:EVAX) will be used to find new antigen combinations for safer vaccine formulation.

The Gates Foundation award allows for strategic R&D advancement without affecting operating expenses, CEO Christian Kanstrup stressed.

Evaxion A/S (NASDAQ:EVAX)’s contribution to the global eradication of infectious diseases through the use of next-generation vaccine technology is strengthened by this project.

While we acknowledge the potential of EVAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EVAX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.